POSC108 Estimated Hospitalization-Related Costs with Oral Azacitidine (ORAL-AZA) vs. Placebo for Remission Maintenance in Patients with Acute Myeloid Leukemia (AML) in Sweden and Norway

Abstract

Hospitalization, often due to relapse, is the largest component (∼70%) of direct healthcare costs in AML. In the international, placebo-controlled QUAZAR AML-001 trial, Oral-AZA significantly prolonged overall and relapse-free survival in patients with AML in remission. We determined hospitalization rates and durations for all patients in QUAZAR AML-001, and estimate associated hospitalization costs in Sweden and Norway.